Reply to Dudoignon et al

Timothy M Rawson; Luke S P Moore; Nina Zhu; Nishanthy Ranganathan; Keira Skolimowska; Mark Gilchrist; Giovanni Satta; Graham Cooke; Alison Holmes

doi:10.1093/cid/ciaa767

Reply to Dudoignon et al

Clin Infect Dis. 2021 Mar 1;72(5):906-908. doi: 10.1093/cid/ciaa767.

Authors

Timothy M Rawson^{1

2

3}, Luke S P Moore^{1

4

5}, Nina Zhu¹, Nishanthy Ranganathan^{3

4}, Keira Skolimowska^{3

4}, Mark Gilchrist^{3

4}, Giovanni Satta^{3

4}, Graham Cooke^{3

4}, Alison Holmes^{1

2

3

4}

Affiliations

¹ National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, London, United Kingdom.
² Centre for Antimicrobial Optimisation, Imperial College London, Hammersmith Campus, London, United Kingdom.
³ Department of Infectious Diseases, Imperial College London, South Kensington Campus, South Kensington, United Kingdom.
⁴ Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom.
⁵ Chelsea and Westminster NHS Foundation Trust, London, United Kingdom.

PMID: 32544234
DOI: 10.1093/cid/ciaa767

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Infective Agents*
COVID-19*
Coinfection*
Coronavirus*
Humans
SARS-CoV-2

Substances

Anti-Infective Agents

Grants and funding

RP-2016-07-012/DH_/Department of Health/United Kingdom